EPHA2 and glioblastoma: In 2020, Orahoske et al. attempted to optimize the EphA2 agonistDoxazosin to identify the lead compounds against GBM.282 A medicinal chemistry campaign was carriedout over Doxazosin (294), and a series of 27 compoundswas introduced by utilizing alkylglycol polyethylene as linkers.